Michael L. Curtin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Michael L. Curtin has a total of 70 co-authors. Here are the top co-authors by number of shared publications:
Michael R. Michaelides
4 shared publicationsSteven K. Davidsen
4 shared publicationsTerrance J. Magoc
4 shared publicationsAlan S. Florjancic
Departments of Cancer Research and Advanced Technology, Global Pharmaceutical Research and Development, Abbott Laboratories, 100 Abbott Park Road, Abbott Park, IL 60064, USA
3 shared publicationsDaniel H. Albert
3 shared publicationsH. Robin Heyman
3 shared publications
Latest Publications
- 1 July 2012
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 22 (14) , 4750-4755
Pyrazole diaminopyrimidines as dual inhibitors of KDR and Aurora B kinases
- 1 July 2012
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 22 (14) , 4750-4755
Pyrazole diaminopyrimidines as dual inhibitors of KDR and Aurora B kinases
- 1 May 2012
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 22 (9) , 3208-3212
Thienopyridine ureas as dual inhibitors of the VEGF and Aurora kinase families
- 1 May 2012
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 22 (9) , 3208-3212
Thienopyridine ureas as dual inhibitors of the VEGF and Aurora kinase families
- 1 November 2004
- Vol. 7 (6) , 848-68
Synthesis of novel hydroxamate and non-hydroxamate histone deacetylase inhibitors.
Histone deacetylases (HDACs) alter the acetylation status of chromatin and thereby effect gene expression. The inappropriate recruitment of HDACs may be one mechanism by which oncogenes can alter gene expression in favor of excessive cell proliferation, making inhibition of HDACs a potential target for the development of small-molecule anticancer agents. As a consequence there are several HDAC inhibitors currently undergoing clinical trials for the treatment of solid and non-solid tumors. This review examines recent synthetic methods used to prepare the diverse family of HDAC inhibitors, and includes syntheses of several of the current clinical candidates. The review is divided into the structural classes of known HDAC inhibitors, including non-peptidic hydroxamic acids, non-hydroxamate analogs and cyclic peptides.
- 1 November 2004
- Vol. 7 (6) , 848-68
Synthesis of novel hydroxamate and non-hydroxamate histone deacetylase inhibitors.
Histone deacetylases (HDACs) alter the acetylation status of chromatin and thereby effect gene expression. The inappropriate recruitment of HDACs may be one mechanism by which oncogenes can alter gene expression in favor of excessive cell proliferation, making inhibition of HDACs a potential target for the development of small-molecule anticancer agents. As a consequence there are several HDAC inhibitors currently undergoing clinical trials for the treatment of solid and non-solid tumors. This review examines recent synthetic methods used to prepare the diverse family of HDAC inhibitors, and includes syntheses of several of the current clinical candidates. The review is divided into the structural classes of known HDAC inhibitors, including non-peptidic hydroxamic acids, non-hydroxamate analogs and cyclic peptides.
- 1 September 2004
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 14 (17) , 4505-4509
Isoindolinone ureas: a novel class of KDR kinase inhibitors
- 1 September 2004
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 14 (17) , 4505-4509
Isoindolinone ureas: a novel class of KDR kinase inhibitors
- 1 November 2003
- Published by Bentham Science Publishers Ltd. in Current Medicinal Chemistry
- Vol. 10 (22) , 2373-2392
Histone Deacetylase Inhibitors: The Abbott Experience
Histone deacetylase inhibitors have generated significant interest as anti-cancer agents due to their ability to cause growth arrest, terminal differentiation and / or apoptosis in carcinoma cells. Abbott entered this area after the serendipitous discovery of the biaryl hydroxamate A-161906 in a TGFβ mimetic screen and the subsequent identification of this compound as an inhibitor of selected HDACs. The complex biology of these enzymes became evident when cloning and expression of the HDACs demonstrated that they were present as multiprotein and, in some cases, multi-HDAC containing complexes in their active forms. This discovery suggested that any selectivity determinations would have to be considered in the context of these multi-protein / HDAC complexes. However, siRNA gene knockdown studies did demonstrate that reduction of the Class I HDACs resulted in a phenotype similar to that observed with small molecule HDAC inhibitors. Evaluation of the Abbott small molecule HDAC inhibitors utilized a Class I HDAC (HDAC 1 / 2) preparation and antiproliferation assays using HT1080 fibrosarcoma and MDA435 breast carcinoma cells. Characterization of several series of hydroxamic acids indicated that while many of these analogs possessed potent enzymatic and cellular activity, in general these compounds had unacceptable pharmacokinetic profiles and marginal antitumor effects. Replacement of the potentially labile hydroxamic acid moiety with a trifluoromethyl ketone or a ketooxazole gave measurable HDAC potency but only modest cellular and in vivo activity. However, hydroxamate replacement with an α-ketoamide moiety provided potent HDAC inhibitors (IC50 values as low as 3 nM) with excellent cellular activity (IC50 values < 0.2 μM) and measurable anti-tumor activity in a flank tumor growth model.
- 1 November 2003
- Published by Bentham Science Publishers Ltd. in Current Medicinal Chemistry
- Vol. 10 (22) , 2373-2392
Histone Deacetylase Inhibitors: The Abbott Experience
Histone deacetylase inhibitors have generated significant interest as anti-cancer agents due to their ability to cause growth arrest, terminal differentiation and / or apoptosis in carcinoma cells. Abbott entered this area after the serendipitous discovery of the biaryl hydroxamate A-161906 in a TGFβ mimetic screen and the subsequent identification of this compound as an inhibitor of selected HDACs. The complex biology of these enzymes became evident when cloning and expression of the HDACs demonstrated that they were present as multiprotein and, in some cases, multi-HDAC containing complexes in their active forms. This discovery suggested that any selectivity determinations would have to be considered in the context of these multi-protein / HDAC complexes. However, siRNA gene knockdown studies did demonstrate that reduction of the Class I HDACs resulted in a phenotype similar to that observed with small molecule HDAC inhibitors. Evaluation of the Abbott small molecule HDAC inhibitors utilized a Class I HDAC (HDAC 1 / 2) preparation and antiproliferation assays using HT1080 fibrosarcoma and MDA435 breast carcinoma cells. Characterization of several series of hydroxamic acids indicated that while many of these analogs possessed potent enzymatic and cellular activity, in general these compounds had unacceptable pharmacokinetic profiles and marginal antitumor effects. Replacement of the potentially labile hydroxamic acid moiety with a trifluoromethyl ketone or a ketooxazole gave measurable HDAC potency but only modest cellular and in vivo activity. However, hydroxamate replacement with an α-ketoamide moiety provided potent HDAC inhibitors (IC50 values as low as 3 nM) with excellent cellular activity (IC50 values < 0.2 μM) and measurable anti-tumor activity in a flank tumor growth model.
- 26 February 2003
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 13 (7) , 1367-1371
Novel and selective imidazole-containing biphenyl inhibitors of protein farnesyltransferase
- 26 February 2003
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 13 (7) , 1367-1371
Novel and selective imidazole-containing biphenyl inhibitors of protein farnesyltransferase
- 1 October 2002
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 12 (20) , 2919-2923
Succinimide hydroxamic acids as potent inhibitors of histone deacetylase (HDAC)
- 1 October 2002
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 12 (20) , 2919-2923
Succinimide hydroxamic acids as potent inhibitors of histone deacetylase (HDAC)
- 1 June 2001
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 11 (12) , 1557-1560
Discovery and characterization of the potent, selective and orally bioavailable MMP inhibitor ABT-770
- 1 June 2001
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 11 (12) , 1557-1560
Discovery and characterization of the potent, selective and orally bioavailable MMP inhibitor ABT-770
- 1 January 1998
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 41 (1) , 74-95
Discovery and Evaluation of a Series of 3-Acylindole Imidazopyridine Platelet-Activating Factor Antagonists
Studies conducted with the goal of discovering a second-generation platelet-activating factor (PAF) antagonist have identified a novel class of potent and orally active antagonists which have high aqueous solubility and long duration of action in animal models. The compounds arose from the combination of the lipophilic indole portion of Abbott's first-generation PAF antagonist ABT-299 (2) with the methylimidazopyridine heterocycle moiety of British Biotechnology's BB-882 (1) and possess the positive attributes of both of these clinical candidates. Structure−activity relationship (SAR) studies indicated that modification of the indole and benzoyl spacer of lead compound 7b gave analogues that were more potent, longer-lived, and bioavailable and resulted in the identification of 1-(N,N-dimethylcarbamoyl)-4-ethynyl-3-{3-fluoro-4-[(1H-2-methylimidazo[4,5-c]pyrid-1-yl)methyl]benzoyl}indole hydrochloride (ABT-491, 22m·HCl) which has been evaluated extensively and is currently in clinical development.
- 1 January 1998
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 41 (1) , 74-95
Discovery and Evaluation of a Series of 3-Acylindole Imidazopyridine Platelet-Activating Factor Antagonists
Studies conducted with the goal of discovering a second-generation platelet-activating factor (PAF) antagonist have identified a novel class of potent and orally active antagonists which have high aqueous solubility and long duration of action in animal models. The compounds arose from the combination of the lipophilic indole portion of Abbott's first-generation PAF antagonist ABT-299 (2) with the methylimidazopyridine heterocycle moiety of British Biotechnology's BB-882 (1) and possess the positive attributes of both of these clinical candidates. Structure−activity relationship (SAR) studies indicated that modification of the indole and benzoyl spacer of lead compound 7b gave analogues that were more potent, longer-lived, and bioavailable and resulted in the identification of 1-(N,N-dimethylcarbamoyl)-4-ethynyl-3-{3-fluoro-4-[(1H-2-methylimidazo[4,5-c]pyrid-1-yl)methyl]benzoyl}indole hydrochloride (ABT-491, 22m·HCl) which has been evaluated extensively and is currently in clinical development.